This phase III trial is comparing a doublet therapy (Nivolumab Combined With Cabozantinib) with a monotherapy (Sunitinib) in patients with advanced renal cell carcinoma that has spread to other parts of the body.
This trial is treating patients with Renal Cell Carcinoma.
This is a systemic therapy trial.
You may be able to join this trial if:
- Your cancer has spread to other parts of the body.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
A Phase 3, Randomized, Open-Label Study of Nivolumab Combined With Cabozantinib Versus Sunitinib in Participants With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
Bristol-Myers Squibb (BMS)
Participants will be randomized to receive monotherapy (Sunitinib) or doublet therapy (Nivolumab and Cabozantinib)
Recruiting Hospitals Read More